author-photo

Alberto Bessudo

AmeriCorps VISTA

48

Papers

477

Citations

Citation Trend

Filter By

Papers (36) Sort By

Journal Conference Others

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (14)
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a lenalidomide-containing combination regimen.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)